Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)

Sponsor
Affiliated Hospital of North Sichuan Medical College
Study ID
NCT03416231
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    apatinib, at a dose of 250 mg daily,Treatment was continued until disease progression.
  • Docetaxel — DRUG
    Docetaxel, at a dose of 75mg/m2 on days 1 and 22, repeat every 4 weeks for 4\~6 cycles.

Study Details

The purpose of this study was to evaluate the effectiveness and safety of apatinib combined with docetaxel in NSCLC.

Key Dates

Start date
Nov 30, 2016
Status verified
Jan 2018
Primary completion
Jan 1, 2019
Completion
Jan 1, 2020

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib plus docetaxel
    apatinib combine with docetaxel， 4\~6 cycles

Primary Outcome Measure

objective response rate (ORR) [ Time Frame: 6 month ]

Central Contacts

Related Studies